Cytokinetics CYTK Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's operating lease liabilities (current)?
- Cytokinetics (CYTK) reported operating lease liabilities (current) of $20.96M in Q1 2026.
- How has Cytokinetics's operating lease liabilities (current) changed year-over-year?
- Cytokinetics's operating lease liabilities (current) increased by 7.1% year-over-year, from $19.57M to $20.96M.
- What is the long-term trend for Cytokinetics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Cytokinetics's operating lease liabilities (current) has grown at a 47.0% compound annual growth rate (CAGR), from $2.79M to $19.11M.
- What does operating lease liabilities (current) mean?
- The amount of lease payments due within one year.
- How do you interpret operating lease liabilities (current)?
- An increase indicates higher near-term cash outflows for leased assets, impacting short-term liquidity.
- How does operating lease liabilities (current) compare across companies?
- Common in companies with significant office or laboratory footprints.